GO:0004427 inorganic diphosphate phosphatase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004427 (inorganic diphosphate phosphatase activity) catalyzes the hydrolysis of diphosphate (pyrophosphate, PPi) into two phosphate ions and a proton, a reaction central to mineral homeostasis and cellular phosphate balance.
• The reaction is essential for preventing pathological calcification because PPi is a potent inhibitor of hydroxyapatite crystal formation in soft tissues and vasculature.
• Multiple enzyme families carry this activity, including alkaline phosphatases (ALPL, ALPP, ALPPL2), ectonucleotide pyrophosphatases/phosphodiesterases (ENPP1, ENPP3), and phospholysine phosphohistidine inorganic pyrophosphate phosphatase (LHPP).
• Loss-of-function mutations in ALPL cause hypophosphatasia, a rare inherited disorder of bone and tooth mineralization, while ENPP1 variants are linked to generalized arterial calcification of infancy and Pseudoxanthoma elasticum-like phenotypes.
• LHPP, a histidine phosphatase with inorganic pyrophosphate phosphatase activity, has emerged as a tumor suppressor and a candidate target in ulcerative colitis.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal dissection of PPi-metabolizing enzymes in mineralization, metabolic, and inflammatory disease contexts.
Description
Inorganic diphosphate phosphatase activity (GO:0004427) is a molecular function defined by the catalytic reaction diphosphate + H2O = H+ + 2 phosphate, in which the high-energy phosphoanhydride bond of pyrophosphate (PPi) is cleaved to yield two molecules of inorganic phosphate. This activity is fundamental to phosphate homeostasis because PPi is generated as a byproduct of numerous biosynthetic reactions, including ATP hydrolysis, DNA and RNA polymerization, and lipid metabolism, and must be continuously removed to prevent its accumulation. Beyond its housekeeping role, PPi is a potent endogenous inhibitor of hydroxyapatite formation, so enzymes that degrade PPi act as gatekeepers of physiological and pathological mineralization. Researchers study GO:0004427 because its dysregulation is directly implicated in vascular calcification, hypophosphatasia, Pseudoxanthoma elasticum, and inflammatory bowel disease, making it a tractable target for both mechanistic and therapeutic investigation. The activity is carried out by structurally diverse enzymes, including tissue-nonspecific alkaline phosphatase (ALPL), ectonucleotide pyrophosphatase/phosphodiesterase family members (ENPP1, ENPP3), and the histidine phosphatase LHPP, each with distinct subcellular localizations and regulatory inputs. Understanding which enzyme supplies inorganic diphosphate phosphatase activity in a given tissue is therefore a central question in mineral and metabolic biology.
inorganic diphosphate phosphatase activity At A Glance
| GO ID | GO:0004427 |
|---|---|
| GO term | inorganic diphosphate phosphatase activity |
| Ontology | molecular_function |
| Definition | Catalysis of the reaction: diphosphate + H2O = H+ + 2 phosphate. |
| Synonym | diphosphate phosphohydrolase activity; inorganic diphosphatase activity; inorganic pyrophosphatase activity; pyrophosphate phosphohydrolase activity |
| Major function | Hydrolysis of pyrophosphate (PPi) into two phosphate ions, controlling cellular phosphate balance and inhibiting pathological mineralization |
| Representative enzymes | ALPL, ALPP, ALPPL2, ENPP1, ENPP3, LHPP, and related phosphatases |
| Substrate | Diphosphate (pyrophosphate, PPi) |
| Products | Two phosphate ions and one proton |
| Disease relevance | Hypophosphatasia, vascular calcification, Pseudoxanthoma elasticum, ulcerative colitis |
What Is GO:0004427?
GO:0004427 describes the catalytic function of hydrolyzing diphosphate (pyrophosphate, PPi) in the presence of water to produce one proton and two phosphate ions, as summarized by the reaction diphosphate + H2O = H+ + 2 phosphate. This is a molecular_function term in the Gene Ontology, and it is synonymous with diphosphate phosphohydrolase activity, inorganic diphosphatase activity, inorganic pyrophosphatase activity, and pyrophosphate phosphohydrolase activity. The activity is not restricted to a single protein family; it is a catalytic capability that can be conferred by alkaline phosphatases, ectonucleotide pyrophosphatases/phosphodiesterases, and histidine phosphatases such as LHPP. Because the substrate PPi is a competitive inhibitor of hydroxyapatite crystal growth, the reaction has outsized physiological importance relative to its simple stoichiometry.
Why Is inorganic diphosphate phosphatase activity Important in Cell Biology?
GO:0004427 is important because it sits at the intersection of phosphate metabolism and biomineralization. Pyrophosphate is a natural inhibitor of hydroxyapatite crystal nucleation and growth, so the enzymes that hydrolyze it determine whether calcium phosphate precipitates in bone, teeth, or soft tissues. When inorganic diphosphate phosphatase activity is insufficient, PPi accumulates and can cause hypophosphatasia-like mineralization defects; when it is excessive or mislocalized, PPi is depleted and vascular or soft-tissue calcification can ensue. The same activity also influences inflammatory signaling, as shown by the identification of LHPP as a protective factor in ulcerative colitis. Consequently, measuring and manipulating GO:0004427 is central to understanding rare genetic mineralization disorders, common age-related vascular disease, and metabolic conditions such as diabetes-associated calcification.
• Controls extracellular PPi levels, which directly determine whether hydroxyapatite crystals form in bone or in soft tissues.
• Loss of ALPL function causes hypophosphatasia, a rare inherited disorder of bone and tooth mineralization.
• ENPP1 dysfunction is associated with generalized arterial calcification and Pseudoxanthoma elasticum-like phenotypes.
• Elevated glucose disrupts extracellular pyrophosphate metabolism and increases vascular calcification risk, linking GO:0004427 to diabetic vascular disease.
• LHPP, a histidine phosphatase with inorganic pyrophosphate phosphatase activity, acts as a tumor suppressor and is a candidate target in ulcerative colitis.
• Alkaline phosphatase, a major carrier of this activity, is a routine clinical biomarker in childhood rickets and bone disease.
• Transcriptional co-regulation of PPi homeostasis genes governs systemic mineralization factors in mice and humans.
• The activity is required for normal skeletal development and for maintaining phosphate homeostasis across tissues.
• Enzymes with this activity are attractive drug targets for calcification disorders and inflammatory bowel disease.
• CRISPR-based models allow causal testing of individual PPi-metabolizing enzymes in disease-relevant cell types.
Molecular Mechanism of inorganic diphosphate phosphatase activity
Substrate recognition and binding of diphosphate
In simple terms: The enzyme grabs a pyrophosphate molecule and holds it in place so it can be cut.
Inorganic diphosphate phosphatase activity begins with binding of the substrate diphosphate (PPi) to the enzyme active site. Alkaline phosphatases such as ALPL and ENPP family members recognize PPi through conserved metal-coordinating residues and a phosphoacceptor site, positioning the phosphoanhydride bond for nucleophilic attack. In the histidine phosphatase LHPP, the active site contains a conserved histidine that becomes phosphorylated during catalysis, defining a distinct catalytic class for the same GO:0004427 activity. Because PPi is a small, highly charged anion, substrate binding is sensitive to local pH, divalent cation availability, and the presence of competing phosphate ions.
Catalytic hydrolysis of the phosphoanhydride bond
In simple terms: Water is used to split pyrophosphate into two phosphate pieces.
The catalytic step of GO:0004427 is the hydrolysis of the PPi phosphoanhydride bond, yielding two phosphate ions and a proton. In alkaline phosphatases, a serine or threonine residue acts as a nucleophile and a zinc-containing active site stabilizes the transition state, while in histidine phosphatases the phosphoenzyme intermediate is formed on a histidine residue. The reaction is essentially irreversible under physiological conditions and is driven by the large free energy of PPi hydrolysis. This step is the defining biochemical event of the GO term and is what distinguishes it from phosphate transport or phosphate-sensing functions.
Cofactors and metal ion requirements
In simple terms: Some helper metals are needed for the enzyme to work properly.
Many enzymes carrying inorganic diphosphate phosphatase activity require divalent metal ions for catalysis. Alkaline phosphatases are zinc metalloenzymes, and their activity is also influenced by magnesium and calcium availability in the extracellular environment. ENPP1 and ENPP3 use zinc and other divalent cations in their catalytic pockets to activate the attacking water molecule. In contrast, LHPP belongs to the histidine phosphatase family and does not require the same zinc-dependent mechanism, illustrating that GO:0004427 can be executed by mechanistically distinct active sites. These cofactor requirements explain why PPi hydrolysis is sensitive to nutritional and metabolic status.
Regulation by substrate availability and transcriptional control
In simple terms: How much pyrophosphate is around, and how much enzyme is made, both control the reaction speed.
The rate of inorganic diphosphate phosphatase activity in cells and tissues is governed by both substrate supply and enzyme abundance. PPi is produced continuously by biosynthetic reactions, so its local concentration sets the flux through GO:0004427. In addition, expression of PPi-metabolizing genes such as ALPL and ENPP1 is transcriptionally co-regulated with other mineralization factors in mice and humans, providing a second layer of control. In disease states, elevated glucose can disrupt extracellular PPi metabolism and shift the balance toward calcification, showing that metabolic context modulates this activity. Post-translational and localization mechanisms further tune which enzyme supplies the activity in a given compartment.
Integration with mineralization and phosphate homeostasis
In simple terms: The reaction acts like a brake on unwanted calcium deposits while supplying phosphate for bone.
The physiological output of GO:0004427 is dual: it removes the mineralization inhibitor PPi and simultaneously releases phosphate, the building block of hydroxyapatite. In bone, ALPL hydrolyzes PPi to provide phosphate for mineral deposition, and loss of this activity causes hypophosphatasia. In soft tissues, ENPP1 generates PPi to inhibit calcification, so its dysfunction leads to ectopic mineralization. Elevated glucose increases vascular calcification risk by disrupting extracellular pyrophosphate metabolism, directly linking GO:0004427 to diabetic vascular pathology. Thus, the same catalytic activity can be protective or pathogenic depending on tissue context and enzyme identity.
Key Genes Involved in GO:0004427 inorganic diphosphate phosphatase activity
The following genes encode enzymes or regulators that carry, control, or are directly tied to inorganic diphosphate phosphatase activity (GO:0004427) in human and mouse biology.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ALPL | Tissue-nonspecific alkaline phosphatase that hydrolyzes PPi to phosphate in bone and teeth | Hypophosphatasia models; bone mineralization studies; clinical biomarker for rickets |
| ALPP | Placental alkaline phosphatase with inorganic diphosphate phosphatase activity | Placental and cancer biology; enzyme kinetics studies |
| ALPPL2 | Alkaline phosphatase-like enzyme contributing to PPi hydrolysis | Reproductive and cancer cell models |
| ENPP1 | Ectonucleotide pyrophosphatase/phosphodiesterase that generates and balances PPi | Vascular calcification and Pseudoxanthoma elasticum models |
| ENPP3 | Ectonucleotide pyrophosphatase/phosphodiesterase family member with PPi-related activity | Allergic and metabolic disease research |
| LHPP | Histidine phosphatase with inorganic pyrophosphate phosphatase activity; tumor suppressor | Ulcerative colitis and cancer target validation |
| PHOSPHO1 | Phosphatase involved in skeletal mineralization and phosphate handling | Bone mineralization and PPi homeostasis studies |
| ANKH | Transmembrane PPi transporter that regulates extracellular PPi available to GO:0004427 enzymes | Craniometaphyseal dysplasia and calcification research |
| ABCC6 | ATP-binding cassette transporter linked to PPi homeostasis and Pseudoxanthoma elasticum | PXE disease modeling and PPi metabolism |
| NT5E | Ecto-5-prime-nucleotidase contributing to extracellular phosphate and PPi balance | Vascular calcification and mineralization genetics |
| TNAP | Tissue-nonspecific alkaline phosphatase (protein product of ALPL) | Skeletal and dental mineralization assays |
| SLC20A1 | Sodium-dependent phosphate transporter influencing phosphate homeostasis | Phosphate sensing and mineralization studies |
| SLC20A2 | Sodium-dependent phosphate transporter involved in phosphate balance | Brain calcification and phosphate research |
| FGF23 | Phosphate-regulating hormone indirectly linked to PPi and phosphate homeostasis | Chronic kidney disease and mineralization models |
| PHEX | Phosphate-regulating endopeptidase linked to mineralization and PPi metabolism | X-linked hypophosphatemia research |
| DMP1 | Dentin matrix protein involved in phosphate and mineral homeostasis | Bone and tooth mineralization models |
How Is inorganic diphosphate phosphatase activity Regulated?
Inorganic diphosphate phosphatase activity is regulated at multiple levels. Transcriptionally, PPi homeostasis genes are co-regulated with systemic mineralization factors in mice and humans, meaning that ALPL, ENPP1, and related genes are expressed in coordinated programs rather than in isolation. Metabolically, substrate availability controls flux through GO:0004427 because PPi is continuously generated by biosynthetic reactions and its local concentration determines reaction rate. In disease contexts, elevated glucose disrupts extracellular pyrophosphate metabolism and increases vascular calcification risk, demonstrating that systemic metabolic state can override normal regulatory control. Enzyme-specific mechanisms also apply: alkaline phosphatases require zinc and are sensitive to pH and divalent cation levels, while LHPP uses a histidine phosphorylation cycle that can be modulated by cellular redox and kinase/phosphatase networks. Finally, extracellular PPi transport by ANKH and ABCC6 determines how much substrate reaches enzymes with GO:0004427 activity, adding a transport-level regulatory layer.
inorganic diphosphate phosphatase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ALPL | Hypophosphatasia; defective bone and tooth mineralization | ALPL knockout osteoblast and iPSC-derived osteoblast models; point-mutation knock-in for patient variants |
| ENPP1 | Generalized arterial calcification; Pseudoxanthoma elasticum-like phenotypes | ENPP1 knockout vascular smooth muscle cells; overexpression in calcification assays |
| ABCC6 | Pseudoxanthoma elasticum; ectopic mineralization | ABCC6 knockout fibroblast models; PPi flux measurements |
| LHPP | Ulcerative colitis; tumor suppression | LHPP knockout intestinal epithelial cells; overexpression in colitis models |
| ALPL/ENPP1 axis | Diabetic vascular calcification | High-glucose-treated vascular cells with CRISPR knockout of PPi enzymes |
Hypophosphatasia and skeletal mineralization disorders
Hypophosphatasia is a rare inherited disorder caused by loss-of-function mutations in ALPL, the gene encoding tissue-nonspecific alkaline phosphatase, which carries inorganic diphosphate phosphatase activity. Because ALPL hydrolyzes PPi to phosphate, its deficiency leads to PPi accumulation, which inhibits hydroxyapatite formation and causes defective bone and tooth mineralization. Clinical presentations range from severe perinatal forms to adult hypophosphatasia, and alkaline phosphatase measurement is central to diagnosis. Childhood rickets is another context in which alkaline phosphatase, a major GO:0004427 enzyme, is used as a clinical biomarker.
Vascular calcification and Pseudoxanthoma elasticum
Vascular calcification is driven in part by an imbalance between PPi production and hydrolysis. Elevated glucose levels increase vascular calcification risk by disrupting extracellular pyrophosphate metabolism, directly implicating GO:0004427 in diabetic vascular disease. Fibroblasts from patients with Pseudoxanthoma elasticum exhibit altered PPi metabolism and are more responsive to pro-calcifying stimuli, linking this activity to ectopic mineralization in connective tissue. ENPP1 and ABCC6 dysfunction further illustrate how PPi homeostasis genes converge on calcification phenotypes.
Ulcerative colitis and inflammation
Single-cell analysis has identified phospholysine phosphohistidine inorganic pyrophosphate phosphatase (LHPP) as a target in ulcerative colitis, expanding the disease relevance of GO:0004427 beyond mineral metabolism. LHPP is a histidine phosphatase with inorganic pyrophosphate phosphatase activity and has been characterized as a tumor suppressor, suggesting that PPi hydrolysis influences cell survival and inflammatory signaling. This positions GO:0004427 as a potential node in both inflammatory bowel disease and cancer biology.
Systemic mineralization and metabolic regulation
Conserved transcriptional co-regulation of pyrophosphate homeostasis genes governs systemic mineralization factors in mice and humans, indicating that GO:0004427 is embedded in a broader genetic network controlling phosphate and mineral balance. Genes such as FGF23, PHEX, DMP1, and SLC20A1/SLC20A2 participate in this network and influence the availability of substrates and cofactors for PPi-hydrolyzing enzymes. This systems-level view helps explain why mutations in different PPi pathway components can produce overlapping mineralization phenotypes.
From inorganic diphosphate phosphatase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of ALPL cause defective mineralization in human osteoblasts? | ALPL knockout iPSC-derived osteoblasts |
| Does a specific patient ALPL variant impair inorganic diphosphate phosphatase activity? | Point-mutation knock-in of the patient allele in a mineralizing cell line |
| Does ENPP1 overexpression protect against vascular calcification? | ENPP1 overexpression in vascular smooth muscle cells under calcifying conditions |
| Does LHPP loss alter inflammatory signaling in intestinal epithelium? | LHPP knockout intestinal organoids or epithelial cell lines |
| How does glucose modulate PPi metabolism and calcification? | High-glucose-treated cells with tagged knock-in of PPi enzymes for localization |
| Which PPi homeostasis genes are co-regulated in bone and vasculature? | CRISPR library screening in mineralizing cell models combined with transcriptomics |
How to Study the inorganic diphosphate phosphatase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Colorimetric phosphate release assay | Inorganic diphosphate phosphatase activity | Validation of ALPL and ENPP1 knockout or mutant cells |
| Single-cell RNA sequencing | Cell-type-specific expression of PPi-metabolizing genes | Discovery of LHPP and other targets in colitis |
| Alizarin Red / calcium quantification | Mineralization and calcification | Vascular calcification and PXE fibroblast studies |
| CRISPR knockout | Loss-of-function phenotype for a candidate gene | Testing ALPL, ENPP1, or LHPP requirement in disease models |
| Point-mutation knock-in | Effect of patient-specific variants | Modeling hypophosphatasia-associated ALPL mutations |
| Overexpression | Sufficiency of an enzyme for PPi hydrolysis or protection | Testing ENPP1 or LHPP protective effects |
| Transcriptomic co-regulation analysis | Coordinate expression of PPi homeostasis genes | Systems-level mineralization studies in mice and humans |
| Clinical alkaline phosphatase measurement | Bone turnover and mineralization status | Diagnosis and monitoring of rickets and hypophosphatasia |
Enzymatic activity assays for inorganic diphosphate phosphatase activity
Direct measurement of GO:0004427 is typically performed using colorimetric or fluorometric assays that detect phosphate release from PPi. Alkaline phosphatase activity assays using p-nitrophenyl phosphate or PPi as substrate are standard for ALPL and related enzymes. These assays can be applied to cell lysates, conditioned media, or purified recombinant proteins and are essential for validating CRISPR knockout or point-mutation effects.
Transcriptomic and single-cell analysis of PPi homeostasis genes
RNA sequencing and single-cell RNA sequencing can reveal which enzymes with inorganic diphosphate phosphatase activity are expressed in a given tissue or cell type. Single-cell analysis identified LHPP as a target in ulcerative colitis, demonstrating the power of this approach for discovering disease-relevant PPi phosphatases. Co-regulation of PPi homeostasis genes with systemic mineralization factors has also been demonstrated using transcriptomic data in mice and humans.
Mineralization and calcification assays
Because PPi inhibits hydroxyapatite formation, functional studies of GO:0004427 often use mineralization assays such as Alizarin Red staining, calcium quantification, and hydroxyapatite crystal formation assays. Fibroblasts from Pseudoxanthoma elasticum patients show altered PPi metabolism and increased responsiveness to pro-calcifying stimuli, making them a useful model for such assays. Vascular calcification studies under high-glucose conditions similarly rely on these readouts.
Genetic and CRISPR-based perturbation
CRISPR knockout, point-mutation knock-in, and overexpression models allow causal testing of individual genes carrying GO:0004427 activity. Knockout of ALPL or ENPP1 in mineralizing cell types can reveal whether a specific enzyme is required for PPi hydrolysis and mineralization. Tagged knock-in approaches enable localization and interaction studies, while overexpression can test sufficiency in calcification or inflammatory models.
How CRISPR Can Be Used to Study GO:0004427 inorganic diphosphate phosphatase activity
Knockout
CRISPR knockout of genes encoding inorganic diphosphate phosphatase activity, such as ALPL, ENPP1, or LHPP, allows researchers to determine whether a specific enzyme is required for PPi hydrolysis and downstream mineralization or inflammatory phenotypes. Knockout models are particularly valuable for distinguishing redundant enzyme activities, since multiple phosphatases can carry GO:0004427. In mineralizing cell types, ALPL knockout recapitulates the biochemical hallmark of hypophosphatasia, namely PPi accumulation and impaired mineralization.
Point Mutation
Point-mutation knock-in models are used to reproduce patient-specific variants in genes such as ALPL that cause hypophosphatasia or other mineralization disorders. By introducing a single amino acid change into the endogenous locus, researchers can assess whether a variant specifically abolishes inorganic diphosphate phosphatase activity without confounding effects from protein truncation. This approach is essential for variant classification and for testing genotype-phenotype relationships in rare disease genetics.
Knock-in
Tagged knock-in of PPi-metabolizing enzymes enables visualization and interaction studies in living cells. Adding fluorescent or affinity tags to ALPL, ENPP1, or LHPP allows tracking of subcellular localization and substrate access, which is important because GO:0004427 activity depends on where PPi is generated and hydrolyzed. Knock-in of reporter cassettes can also be used to monitor transcriptional regulation of PPi homeostasis genes in response to metabolic cues such as glucose.
Overexpression
Overexpression models test whether increasing the amount of an enzyme with inorganic diphosphate phosphatase activity is sufficient to alter disease phenotypes. For example, overexpression of ENPP1 or LHPP can be used to ask whether enhanced PPi hydrolysis protects against vascular calcification or intestinal inflammation. These models complement knockout studies by establishing sufficiency rather than necessity and are useful for target validation in drug discovery.
How EDITGENE Supports inorganic diphosphate phosphatase activity Research
Researchers studying inorganic diphosphate phosphatase activity-related genes often need to determine whether a candidate gene is causally involved in mineralization, inflammation, or metabolic disease. EDITGENE provides CRISPR-based cell model services that enable precise, reproducible perturbation of PPi-metabolizing enzymes in disease-relevant cell types.
Contact EDITGENE today to design your custom CRISPR model for inorganic diphosphate phosphatase activity research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| PPA2 Knockout HEK293 Cell Line | EDJ-KQ8663 | Human | 27068 | Details Get a Quote |
| LHPP Knockout HEK293 Cell Line | EDJ-KQ14068 | Human | 64077 | Details Get a Quote |
| ALPL Knockout HEK293 Cell Line | EDC08024 | Human | 249 | Details Get a Quote |
| ALPL Knockout HeLa Cell Line | EDJ-KQ22028 | Human | 249 | Details Get a Quote |
| LHPP Knockout A-549 Cell Line | EDJ-KQ43974 | Human | 64077 | Details Get a Quote |
| LHPP Knockout HCT 116 Cell Line | EDJ-KQ43975 | Human | 64077 | Details Get a Quote |
| LHPP Knockout HeLa Cell Line | EDJ-KQ43976 | Human | 64077 | Details Get a Quote |
| PPA2 Knockout HCT 116 Cell Line | EDJ-KQ34837 | Human | 27068 | Details Get a Quote |
| PPA2 Knockout HeLa Cell Line | EDJ-KQ34838 | Human | 27068 | Details Get a Quote |
| ALPL Knockout A-549 Cell Line | EDJ-KQ61079 | Human | 249 | Details Get a Quote |
| PPA2 Knockout A-549 Cell Line | EDJ-KQ64478 | Human | 27068 | Details Get a Quote |
| ALPL Knockout HCT 116 Cell Line | EDJ-KQ69561 | Human | 249 | Details Get a Quote |
Displaying Records 1 To 12 Of 12 Records
Frequently Asked Questions About inorganic diphosphate phosphatase activity
What is inorganic diphosphate phosphatase activity?
Inorganic diphosphate phosphatase activity (GO:0004427) is the catalytic hydrolysis of diphosphate (pyrophosphate, PPi) into two phosphate ions and a proton, as defined by the reaction diphosphate + H2O = H+ + 2 phosphate.
What genes are involved in inorganic diphosphate phosphatase activity?
Genes encoding enzymes with this activity include ALPL, ALPP, ALPPL2, ENPP1, ENPP3, and LHPP, along with regulators such as ANKH and ABCC6 that control PPi availability.
What is the GO ID for inorganic diphosphate phosphatase activity?
The Gene Ontology identifier is GO:0004427, classified under the molecular_function aspect.
Why is pyrophosphate hydrolysis important for bone mineralization?
PPi inhibits hydroxyapatite crystal formation, so its hydrolysis by enzymes such as ALPL provides phosphate for bone mineral deposition while removing the inhibitor.
How is inorganic diphosphate phosphatase activity measured?
It is commonly measured using colorimetric or fluorometric phosphate release assays with PPi or p-nitrophenyl phosphate as substrate, applied to cell lysates or purified enzymes.
What diseases are linked to defects in inorganic diphosphate phosphatase activity?
Hypophosphatasia, vascular calcification, Pseudoxanthoma elasticum, and ulcerative colitis have been linked to altered PPi metabolism and this activity.
What is the role of ALPL in hypophosphatasia?
ALPL encodes tissue-nonspecific alkaline phosphatase, and loss-of-function mutations reduce PPi hydrolysis, causing PPi accumulation and defective bone and tooth mineralization characteristic of hypophosphatasia.
How does glucose affect pyrophosphate metabolism?
Elevated glucose levels increase vascular calcification risk by disrupting extracellular pyrophosphate metabolism, linking metabolic status to GO:0004427 function.
What is LHPP and how does it relate to this GO term?
LHPP is a phospholysine phosphohistidine inorganic pyrophosphate phosphatase with inorganic pyrophosphate phosphatase activity, and it has been identified as a target in ulcerative colitis and as a tumor suppressor.
Can CRISPR be used to study inorganic diphosphate phosphatase activity?
Yes, CRISPR knockout, point-mutation knock-in, tagged knock-in, and overexpression models allow causal testing of individual PPi-metabolizing enzymes in mineralization and inflammation research.
Conclusion
Inorganic diphosphate phosphatase activity (GO:0004427) is a deceptively simple catalytic function with far-reaching consequences for phosphate homeostasis and biomineralization. By hydrolyzing pyrophosphate, enzymes such as ALPL, ENPP1, and LHPP control whether calcium phosphate is deposited in bone or in soft tissues, and their dysfunction underlies hypophosphatasia, vascular calcification, Pseudoxanthoma elasticum, and inflammatory disease. The transcriptional co-regulation of PPi homeostasis genes with systemic mineralization factors further highlights the systems-level importance of this activity. Continued research using CRISPR-based cell models will be essential for assigning specific disease phenotypes to individual enzymes and for developing targeted therapies.
References
- 1. Flores-Roco A et al.. 2024. Elevated glucose levels increase vascular calcification risk by disrupting extracellular pyrophosphate metabolism.. Cardiovasc Diabetol 23(1):405 PMID: 39529124
- 2. Tamatey V et al.. 2026. Conserved transcriptional co-regulation of pyrophosphate homeostasis genes governs systemic mineralization factors in mice and humans.. Mol Metab 111:102415 PMID: 42431310
- 3. Boraldi F et al.. 2014. Fibroblasts from patients affected by Pseudoxanthoma elasticum exhibit an altered PPi metabolism and are more responsive to pro-calcifying stimuli.. J Dermatol Sci 74(1):72-80 PMID: 24461675
- 4. Sorensen E et al.. 1975. Adult hypophosphatasia.. Acta Med Scand 197(5):357-60 PMID: 167553
- 5. Rezende LA et al.. 1998. Inorganic pyrophosphate-phosphohydrolytic activity associated with rat osseous plate alkaline phosphatase.. Cell Mol Biol (Noisy-le-grand) 44(2):293-302 PMID: 9593580
- 6. Terheggen HG et al.. 1984. [Congenital hypophosphatasia].. Monatsschr Kinderheilkd 132(7):512-22 PMID: 6147751
- 7. Wang YF et al.. 2023. Single-cell analysis identifies phospholysine phosphohistidine inorganic pyrophosphate phosphatase as a target in ulcerative colitis.. World J Gastroenterol 29(48):6222-6234 PMID: 38186864
- 8. Cannalire G et al.. 2023. Alkaline phosphatase in clinical practice in childhood: Focus on rickets.. Front Endocrinol (Lausanne) 14:1111445 PMID: 36817604
